skin neoplasms

Summary

Summary: Tumors or cancer of the SKIN.

Top Publications

  1. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
  2. pmc Final version of 2009 AJCC melanoma staging and classification
    Charles M Balch
    Department of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
    J Clin Oncol 27:6199-206. 2009
  3. ncbi Distinct sets of genetic alterations in melanoma
    John A Curtin
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143 0808, USA
    N Engl J Med 353:2135-47. 2005
  4. ncbi BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma
    Maria Colombino
    Istituto Chimica Biomolecolare, Consiglio Nazionaledelle Ricerche, Italy
    J Clin Oncol 30:2522-9. 2012
  5. ncbi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
  6. ncbi Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
    C M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:3622-34. 2001
  7. ncbi Incidence estimate of nonmelanoma skin cancer in the United States, 2006
    Howard W Rogers
    Advanced Dermatology, 111 Salem Turnpike, Norwich, CT 06360, USA
    Arch Dermatol 146:283-7. 2010
  8. ncbi Melanoma
    Arlo J Miller
    Dermatopathology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 355:51-65. 2006
  9. ncbi Melanoma biology and new targeted therapy
    Vanessa Gray-Schopfer
    The Institute of Cancer Research, Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
    Nature 445:851-7. 2007
  10. pmc Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    Nikhil Wagle
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
    J Clin Oncol 29:3085-96. 2011

Research Grants

Detail Information

Publications273 found, 100 shown here

  1. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
    ....
  2. pmc Final version of 2009 AJCC melanoma staging and classification
    Charles M Balch
    Department of Surgery, Oncology and Dermatology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
    J Clin Oncol 27:6199-206. 2009
    ..To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database...
  3. ncbi Distinct sets of genetic alterations in melanoma
    John A Curtin
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143 0808, USA
    N Engl J Med 353:2135-47. 2005
    ..We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light...
  4. ncbi BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma
    Maria Colombino
    Istituto Chimica Biomolecolare, Consiglio Nazionaledelle Ricerche, Italy
    J Clin Oncol 30:2522-9. 2012
    ..The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the prevalence and distribution of mutations in these genes in different melanoma tissues...
  5. ncbi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
    ..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
  6. ncbi Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
    C M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:3622-34. 2001
    ..Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,450 melanoma patients from their databases in order to validate this staging proposal...
  7. ncbi Incidence estimate of nonmelanoma skin cancer in the United States, 2006
    Howard W Rogers
    Advanced Dermatology, 111 Salem Turnpike, Norwich, CT 06360, USA
    Arch Dermatol 146:283-7. 2010
    ..To estimate the incidence of nonmelanoma skin cancer (NMSC) in the US population in 2006 and secondarily to indicate trends in numbers of procedures for skin cancer treatment...
  8. ncbi Melanoma
    Arlo J Miller
    Dermatopathology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 355:51-65. 2006
  9. ncbi Melanoma biology and new targeted therapy
    Vanessa Gray-Schopfer
    The Institute of Cancer Research, Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
    Nature 445:851-7. 2007
    ..Recent discoveries in cell signalling have provided greater understanding of the biology that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches...
  10. pmc Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    Nikhil Wagle
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
    J Clin Oncol 29:3085-96. 2011
    ..These results provide an instructive framework for assessing mechanisms of acquired resistance to kinase inhibition and illustrate the use of emerging technologies in a manner that may accelerate personalized cancer medicine...
  11. ncbi Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
    Sergey I Nikolaev
    Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland
    Nat Genet 44:133-9. 2012
    ..Furthermore, missense and nonsense somatic mutations were frequently found in three candidate melanoma genes, FAT4, LRP1B and DSC1...
  12. ncbi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    ..To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome...
  13. pmc gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
    Douglas J Schwartzentruber
    Indiana University Health Goshen Center for Cancer Care, Goshen, IN 46526, USA
    N Engl J Med 364:2119-27. 2011
    ....
  14. pmc Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada
    Nature 457:599-602. 2009
    ..Our results demonstrate an alternative route to MAP kinase activation in melanocytic neoplasia, providing new opportunities for therapeutic intervention...
  15. ncbi Somatic activation of KIT in distinct subtypes of melanoma
    John A Curtin
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143 0808, USA
    J Clin Oncol 24:4340-6. 2006
    ..This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS...
  16. ncbi De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin
    U Gat
    Howard Hughes Medical Institute, The University of Chicago, Illinois 60637, USA
    Cell 95:605-14. 1998
    ..Our findings suggest that transient beta-catenin stabilization may be a key player in the long-sought epidermal signal leading to hair development and implicate aberrant beta-catenin activation in hair tumors...
  17. ncbi Melanocyte biology and skin pigmentation
    Jennifer Y Lin
    Harvard Combined Program in Dermatology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02115, USA
    Nature 445:843-50. 2007
    ..Skin is the most common site of cancer in humans. Continued understanding of melanocyte contributions to skin biology will hopefully provide new opportunities for the prevention and treatment of skin diseases...
  18. pmc Characterization of the Melanoma miRNAome by Deep Sequencing
    Mitchell S Stark
    Oncogenomics Laboratory, Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia
    PLoS ONE 5:e9685. 2010
    ..We therefore undertook a comprehensive analysis of the miRNAome in a diverse range of pigment cells including: melanoblasts, melanocytes, congenital nevocytes, acral, mucosal, cutaneous and uveal melanoma cells...
  19. ncbi Efficacy and safety of vismodegib in advanced basal-cell carcinoma
    Aleksandar Sekulic
    Mayo Clinic, Scottsdale, AZ 85259, USA
    N Engl J Med 366:2171-9. 2012
    ..A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma...
  20. ncbi Activating Smoothened mutations in sporadic basal-cell carcinoma
    J Xie
    Department of Dermatology, San Francisco General Hospital, University of California, 94110, USA
    Nature 391:90-2. 1998
    ..These findings support the role of SMO as a signalling component of the SHH-receptor complex and provide direct evidence that mutated SMO can function as an oncogene in BCCs...
  21. ncbi Apoptosis and melanoma chemoresistance
    Maria S Soengas
    Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 28109, USA
    Oncogene 22:3138-51. 2003
    ..With this knowledge in hand, the challenge is now to devise strategies potent enough to compensate or bypass these cell death defects and improve the actual poor prognosis of patients at late stages of the disease...
  22. pmc Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing
    Mitchell S Stark
    Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Nat Genet 44:165-9. 2012
    ..Attenuation of MAP3K9 function in melanoma cells using siRNA led to increased cell viability after temozolomide treatment, suggesting that decreased MAP3K pathway activity can lead to chemoresistance in melanoma...
  23. ncbi Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008
    ....
  24. ncbi Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
    Kim Margolin
    University of Washington, Seattle, WA 98109, USA
    Lancet Oncol 13:459-65. 2012
    ..Ipilimumab improves survival in patients with advanced melanoma. We aimed to investigate the safety and activity of this drug specifically in patients with brain metastases...
  25. ncbi Signatures of microRNAs and selected microRNA target genes in human melanoma
    Demetra Philippidou
    Life Sciences Research Unit, University of Luxembourg, Freiburg, Germany
    Cancer Res 70:4163-73. 2010
    ..Our findings define miRNAs and miRNA target genes that offer candidate biomarkers in human melanoma...
  26. ncbi Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System
    Jill S Barnholtz-Sloan
    Karmanos Cancer Institute, Wayne State University School of Medicine, 110 E Warren, Detroit, MI 48201, USA
    J Clin Oncol 22:2865-72. 2004
    ..The purpose of this study was to calculate population-based incidence proportions (IPs) of brain metastases from single primary lung, melanoma, breast, renal, or colorectal cancer...
  27. pmc Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
    Todd D Prickett
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Genet 41:1127-32. 2009
    ..These studies could lead to personalized therapeutics specifically targeting the kinases that are mutationally altered in individual melanomas...
  28. ncbi The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms
    Federica Felicetti
    Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore Sanita, Rome, Italy
    Cancer Res 68:2745-54. 2008
    ....
  29. ncbi Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis
    Simone Mocellin
    Clinica Chirurgica Generale 2, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    J Natl Cancer Inst 102:493-501. 2010
    ..However, RCTs have yielded conflicting data on the effect of IFN-alpha on overall survival (OS)...
  30. ncbi Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential
    Elena Monzani
    Department of Biomolecular Science and Biotechnology, University of Milan, Milan, Italy
    Eur J Cancer 43:935-46. 2007
    ..Interestingly, considering that melanoma gives metastasis primarily through lymphatic vessels, herein, we demonstrated that a melanoma cell line expresses typical lymphoangiogenic factors...
  31. ncbi Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet
    Giuseppe Argenziano
    Department of Dermatology, Second University of Naples, Italy
    J Am Acad Dermatol 48:679-93. 2003
    ..There is a need for better standardization of the dermoscopic terminology in assessing pigmented skin lesions...
  32. ncbi S100A8 and S100A9 in inflammation and cancer
    Christoffer Gebhardt
    Division of Signal Transduction and Growth Control, German Cancer Research Center, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
    Biochem Pharmacol 72:1622-31. 2006
    ..Altogether, its expression and potential cytokine-like function in inflammation and in cancer suggests that S100A8/A9 may play a key role in inflammation-associated cancer...
  33. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma...
  34. pmc Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases
    Charles M Balch
    Department of Surgery, Johns Hopkins Medical Institutions, 600 N Wolfe St, Osler 624, Baltimore, MD 21287, USA
    J Clin Oncol 28:2452-9. 2010
    ..To determine the survival rates and independent predictors of survival using a contemporary international cohort of patients with stage III melanoma...
  35. pmc Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens
    Roland Houben
    Molecular Virology Program, University of Pittsburgh Cancer Institute, 5117 Centre Ave, Pittsburgh, PA 15213, USA
    J Virol 84:7064-72. 2010
    ..Our study provides the first direct experimental evidence that TA expression is necessary for the maintenance of MCV-positive MCC and that MCV is the infectious cause of MCV-positive MCC...
  36. ncbi Identification of the familial cylindromatosis tumour-suppressor gene
    G R Bignell
    1 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 25:160-5. 2000
    ..CYLD also has sequence homology to the catalytic domain of ubiquitin carboxy-terminal hydrolases (UCH)...
  37. pmc Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma
    Sarah T Arron
    Department of Dermatology, University of California, San Francisco, San Francisco, CA 94143, USA
    J Invest Dermatol 131:1745-53. 2011
    ..In contrast, HPV16 and HPV18 mRNA transcripts were readily identified in primary cervical and periungual cancers and HeLa cells. These data demonstrate that papillomavirus mRNA expression is not a factor in the maintenance of cuSCCs...
  38. pmc Clonal integration of a polyomavirus in human Merkel cell carcinoma
    Huichen Feng
    Molecular Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Suite 1 8, Pittsburgh, PA 15213, USA
    Science 319:1096-100. 2008
    ..Thus, MCV may be a contributing factor in the pathogenesis of MCC...
  39. pmc Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications
    Erika L Abel
    Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, Texas, USA
    Nat Protoc 4:1350-62. 2009
    ..In contrast to complete skin carcinogenesis, the two-stage model allows for greater yield of premalignant lesions, as well as separation of the initiation and promotion phases...
  40. pmc Genetic variants in telomere-maintaining genes and skin cancer risk
    Hongmei Nan
    Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Hum Genet 129:247-53. 2011
    ..05). We did not observe significant associations for SCC or BCC risk. Our study provides evidence for the contribution of genetic variants in the telomere-maintaining genes to melanoma susceptibility...
  41. pmc Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma
    Carmit Levy
    Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 40:841-9. 2010
    ..These data implicate miR-211 as a suppressor of melanoma invasion whose expression is silenced or selected against via suppression of the entire melastatin locus during human melanoma progression...
  42. pmc Genome-wide association study identifies novel loci predisposing to cutaneous melanoma
    Christopher I Amos
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Hum Mol Genet 20:5012-23. 2011
    ..3 rs7412746 (P = 6 × 10(-10)). Together, these data identified several candidate genes for additional studies to identify causal variants predisposing to increased risk for developing melanoma...
  43. ncbi Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature
    Sheela G Gupta
    Cutaneous Oncology Disease Center, Dana Farber Brigham and Women s Cancer Center, Boston, Mass, USA
    Arch Dermatol 142:685-90. 2006
    ..To determine the diagnostic accuracy and usefulness of sentinel lymph node biopsy (SLNB) and computed tomographic scans in the initial evaluation and treatment of patients with Merkel cell carcinoma (MCC)...
  44. ncbi Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 11:155-64. 2010
    ..Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma...
  45. pmc Role of integrins in regulating epidermal adhesion, growth and differentiation
    Fiona M Watt
    Cancer Research UK, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    EMBO J 21:3919-26. 2002
    ..In this review I summarize what is known about the expression and function of epidermal integrins, and highlight the challenges for future research...
  46. ncbi Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia
    Pamela M Pollock
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Genet 34:108-12. 2003
    ..This study provides compelling evidence for the importance of metabotropic glutamate signaling in melanocytic neoplasia...
  47. pmc Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials
    Christine M Lovly
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 7:e35309. 2012
    ....
  48. pmc Increasing burden of melanoma in the United States
    Eleni Linos
    Northern California Cancer Center, Fremont, California, USA
    J Invest Dermatol 129:1666-74. 2009
    ..We conclude that screening-associated diagnosis of thinner melanomas cannot explain the increasing rates of thicker melanomas among low SES populations with poorer access to screening...
  49. ncbi Melanoma epidemiology and trends
    Claus Garbe
    Division of Dermato oncology, Eberhard Karls University, 72076 Tuebingen, Germany
    Clin Dermatol 27:3-9. 2009
    ..This development indicates improved early recognition of cutaneous melanoma, which is presently the main factor for a more favorable prognosis...
  50. pmc Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
    Jill C Rubinstein
    Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Transl Med 8:67. 2010
    ..Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations...
  51. pmc Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W 3940, 10 Center Dr, Bethesda, MD 20892 1201, USA
    J Clin Oncol 23:6043-53. 2005
    ..We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression...
  52. pmc Germline mutations in BAP1 predispose to melanocytic tumors
    Thomas Wiesner
    Department of Dermatology, Medical University of Graz, Graz, Austria
    Nat Genet 43:1018-21. 2011
    ..These findings suggest that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytic neoplasm...
  53. pmc From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma
    Vladimir Ratushny
    Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Clin Invest 122:464-72. 2012
    ..Insights gained from modeling cSCCs have suggested innovative therapeutic targets for treating these lesions...
  54. pmc High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays
    Roland Houben
    Department of Dermatology, University Hospital Wurzburg, Wurzburg, Germany
    PLoS ONE 6:e22096. 2011
    ..However, the mutational status of p53 in melanoma is still controversial; to clarify this notion we analysed the largest series of melanoma samples reported to date...
  55. ncbi Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis
    Natasa Vasiljevic
    Department of Laboratory Medicine, Division of Medical Microbiology, Lund University, University Hospital, Malmo, Sweden
    J Gen Virol 89:2467-74. 2008
    ..However, as these types were found in only a few samples and in low amounts, a possible role in carcinogenesis remains elusive...
  56. ncbi Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
    M B Lens
    John Radcliffe Hospital, University of Oxford, Oxford, UK
    Br J Dermatol 150:179-85. 2004
    ..Trends in melanoma incidence worldwide are examined. The most recent data on the mortality from cutaneous melanoma are reported. The role of different environmental, genetic and host factors in the aetiology of melanoma is discussed...
  57. ncbi p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition
    Zhenyu Ji
    Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Invest Dermatol 132:356-64. 2012
    ..These results provide fundamental insights into the intact p53 circuitry, which can be restored through small molecule inhibitors and potentially deployed for therapeutic gain...
  58. pmc Identifying the cellular origin of squamous skin tumors
    Gaelle Lapouge
    Institut de Recherche Interdisciplinaire en Biologie Humaine et Moleculaire, Universite Libre de Bruxelles, B 1070 Brussels, Belgium
    Proc Natl Acad Sci U S A 108:7431-6. 2011
    ..Our studies demonstrate that different epidermal lineages including bulge SC are competent to initiate papilloma formation and that multiple genetic hits in the context of oncogenic KRas are required for the development of invasive SCC...
  59. pmc RAGE signaling sustains inflammation and promotes tumor development
    Christoffer Gebhardt
    Division of Signal Transduction and Growth Control, German Cancer Research Center, 69120 Heidelberg, Germany
    J Exp Med 205:275-85. 2008
    ..We show that RAGE signaling drives the strength and maintenance of an inflammatory reaction during tumor promotion and provide direct genetic evidence for a novel role for RAGE in linking chronic inflammation and cancer...
  60. pmc miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein
    Altaf A Dar
    California Pacific Medical Center Research Institute, San Francisco, California 94107, USA
    J Biol Chem 286:16606-14. 2011
    ..E2F1 overexpression in miR-205-expressing cells partially reversed the effects on melanoma cell growth and senescence. These results demonstrate a novel role for miR-205 as a tumor suppressor in melanoma...
  61. ncbi The melanocortin-1-receptor gene is the major freckle gene
    M Bastiaens
    Department of Dermatology and Department of Clinical Epidemiology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands
    Hum Mol Genet 10:1701-8. 2001
    ..The results of the study also suggest that MC1R gene variants play a role, although less important, in the development of solar lentigines...
  62. ncbi Merkel cell carcinoma: prognosis and treatment of patients from a single institution
    Peter J Allen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021 e mail
    J Clin Oncol 23:2300-9. 2005
    ..Merkel cell carcinoma (MCC) is an uncommon cutaneous malignancy. Most reports consist of single-institution experiences of fewer than 30 patients. The natural history of MCC is poorly defined...
  63. ncbi A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
    Jeffrey Weber
    Moffitt Cancer Center, Tampa, Florida 33612, USA
    Clin Cancer Res 15:5591-8. 2009
    ....
  64. ncbi Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca
    Elise Olsen
    Department of Medicine, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, NC 27516, USA
    Blood 110:1713-22. 2007
    ..The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions...
  65. ncbi Deregulated Akt3 activity promotes development of malignant melanoma
    Jill M Stahl
    Department of Pharmacology, The Pennsylvania State College of Medicine, Hershey, Pennsylvania 17033, USA
    Cancer Res 64:7002-10. 2004
    ..Identifying Akt3 as a selective target in melanoma cells provides new therapeutic opportunities for patients in the advanced stages of this disease...
  66. ncbi Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome
    Goran Jonsson
    Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
    Clin Cancer Res 16:3356-67. 2010
    ..Although spontaneous regression, likely due to immune defense activation, rarely occurs, we lack a biological rationale and predictive markers in selecting patients for immune therapy...
  67. ncbi Molecular diagnostics in melanoma
    J Andrew Carlson
    Division of Dermatopathology, Albany Medical College, Albany, New York 12208, USA
    J Am Acad Dermatol 52:743-75; quiz 775-8. 2005
    ..Herein, molecular diagnostics that can potentially benefit the individual melanoma patient will be discussed...
  68. ncbi Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight
    Ulrike Leiter
    Division of Dermatoloncology, Department of Dermatology, University Medical Center, University of Tuebingen, Liebermeisterstr, 25, 72076 Tuebingen, Germany
    Adv Exp Med Biol 624:89-103. 2008
    ..In contrast to squamous cell carcinoma, melanoma risk seems not to be associated with cumulative, but intermittent exposure to sunlight. Therefore campaigns for prevention and early detection are necessary...
  69. pmc New common variants affecting susceptibility to basal cell carcinoma
    Simon N Stacey
    deCODE Genetics, Reykjavik, Iceland
    Nat Genet 41:909-14. 2009
    ..Finally, we report conclusive evidence that rs401681[C] in the TERT-CLPTM1L locus confers susceptibility to BCC but protects against melanoma...
  70. pmc MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
    L M Coussens
    Cancer Research Institute, University of California, San Francisco 94143, USA
    Cell 103:481-90. 2000
    ..Thus, inflammatory cells can be coconspirators in carcinogenesis...
  71. pmc Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features
    Michelle Heath
    University of Washington, Division of Dermatology, Seattle, Washington 98109, USA
    J Am Acad Dermatol 58:375-81. 2008
    ..Advanced disease at diagnosis is a poor prognostic factor, suggesting that earlier detection may improve outcome. No systematic analysis has been published to define the clinical features that are characteristic of MCC...
  72. ncbi Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours
    Cristina Lo Celso
    Keratinocyte Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Development 131:1787-99. 2004
    ..We conclude that interfollicular epidermis and sebaceous glands retain the ability to be reprogrammed in adult life and that continuous beta-catenin signalling is required to maintain hair follicle tumours...
  73. pmc Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
    Liesbeth C W Vredeveld
    Division of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    Genes Dev 26:1055-69. 2012
    ....
  74. ncbi FOXM1 is a downstream target of Gli1 in basal cell carcinomas
    Muy Teck Teh
    Centre for Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London E1 2AT, United Kingdom
    Cancer Res 62:4773-80. 2002
    ....
  75. ncbi Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
    Sara Gandini
    Department of Epidemiology and Biostatistics, European Institute of Oncology, IRCCS Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:45-60. 2005
    ....
  76. pmc Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays
    Yanis L Tolstov
    Molecular Virology Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Int J Cancer 125:1250-6. 2009
    ..Our study demonstrates that MCV is a widespread but previously unrecognized human infection...
  77. ncbi A systematic review of worldwide incidence of nonmelanoma skin cancer
    A Lomas
    University of Nottingham, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Br J Dermatol 166:1069-80. 2012
    ..Nonmelanoma skin cancer (NMSC) is the most common cancer affecting white-skinned individuals and the incidence is increasing worldwide...
  78. ncbi Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi
    Sara Gandini
    Department of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:28-44. 2005
    ..Case-control studies, in particular when the hospital was the source for cases or controls, appeared to present much lower and more precise estimates than cohort studies...
  79. ncbi Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis
    Gary M Halliday
    Dermatology Research Laboratories, Division of Medicine, Melanoma and Skin Cancer Research Institute, Royal Prince Alfred Hospital at the University of Sydney, Sydney, NSW, Australia
    Mutat Res 571:107-20. 2005
    ..Available evidence implicates oxidative damage as an important contributor to sunlight-induced carcinogenesis in humans...
  80. ncbi Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis
    Howard F Tiano
    Laboratory of Experimental Carcinogenesis and Mutagenesis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA
    Cancer Res 62:3395-401. 2002
    ..Thus, both COX-1 and COX-2 have roles in keratinocyte differentiation, and we propose that the absence of either isoform causes premature terminal differentiation of initiated keratinocytes and reduced tumor formation...
  81. ncbi NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
    Esther Edlundh-Rose
    Department of Gene Technology, School of Biotechnology, Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
    Melanoma Res 16:471-8. 2006
    ..7). In conclusion, the separate genotypes were associated with differences in several key clinical and pathological parameters, indicating differences in the biology of melanoma tumours with different proto-oncogene mutations...
  82. ncbi An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells
    Roland Houben
    Department of Dermatology, University Hospital Wurzburg, Wurzburg, Germany
    Int J Cancer 130:847-56. 2012
    ..Consequently, interference with LTA/RB interaction appears as promising strategy to treat MCC...
  83. pmc Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis
    Mathieu Boniol
    International Prevention Research Institute, 95 cours Lafayette, 69006 Lyon, France
    BMJ 345:e4757. 2012
    ..To estimate the burden of melanoma resulting from sunbed use in western Europe...
  84. ncbi Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays
    Mitchell Stark
    Oncogenomics Laboratory, Queensland Institute of Medical Research, Herston, Queensland, Australia
    Cancer Res 67:2632-42. 2007
    ....
  85. pmc KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
    ..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...
  86. pmc β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas
    William E Damsky
    Department of Dermatology, Yale University School of Medicine, New Haven, CT 06510, USA
    Cancer Cell 20:741-54. 2011
    ..Highly metastatic tumors with β-catenin stabilization are very similar to a subset of human melanomas. Together these findings establish Wnt signaling as a metastasis regulator in melanoma...
  87. ncbi Non-melanoma skin cancer: what drives tumor development and progression?
    Petra Boukamp
    Division of Genetics of Skin Carcinogenesis, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
    Carcinogenesis 26:1657-67. 2005
    ..However, the complexity of the genetic alterations (numerical and structural aberration profiles) in SCCs argues for several levels of genomic instability involved in the generation and progression of skin cancer...
  88. pmc New perspectives on the role of vitiligo in immune responses to melanoma
    Katelyn T Byrne
    Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH, USA
    Oncotarget 2:684-94. 2011
    ..We also discuss the implications of our recent findings for the interpretation of patient responses, and the design of next-generation cancer immunotherapies...
  89. ncbi Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny
    Y Cheli
    INSERM, U895, Centre Méditerranéen de Médecine Moléculaire, Equipe 1, Biology and Pathologies of Melanocytes, Equipe Labellisée LIGUE 2010, Nice, France
    Oncogene 30:2307-18. 2011
    ..Taken together our data, identified Mitf and p27 as the key molecular switches that control the transition between MICs and their differentiated progeny. Eradication of low-Mitf cells might be an appealing strategy to cure melanoma...
  90. ncbi Prevalence of sunburn, sun protection, and indoor tanning behaviors among Americans: review from national surveys and case studies of 3 states
    David B Buller
    Klein Buendel Inc, Golden, Colorado 80439, USA
    J Am Acad Dermatol 65:S114-23. 2011
    ..Exposure to ultraviolet radiation (from solar and nonsolar sources) is a risk factor for skin cancer...
  91. ncbi Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    J Clin Oncol 20:3586-91. 2002
    ..We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate...
  92. ncbi MicroRNA expression profiles associated with mutational status and survival in malignant melanoma
    Stefano Caramuta
    Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
    J Invest Dermatol 130:2062-70. 2010
    ..The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice...
  93. ncbi Expression of platelet-derived growth factor-beta receptor and bovine papillomavirus E5 and E7 oncoproteins in equine sarcoid
    G Borzacchiello
    Department of Pathology and Animal Health, Faculty of Veterinary Medicine, Naples University Federico II, Via F Delpino 1, 80137 Naples
    J Comp Pathol 139:231-7. 2008
    ..These findings add further weight to the theory that BPV and the PDGF-betaR may have a role in the pathogenesis of this disease...
  94. pmc Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model
    Andy J Chien
    Institute for Stem Cell and Regenerative Medicine, Department of Medicine, Division of Dermatology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 106:1193-8. 2009
    ..Our results may explain the observed loss of nuclear beta-catenin with melanoma progression in human tumors, which could reflect a dysregulation of cellular differentiation through a loss of homeostatic Wnt/beta-catenin signaling...
  95. ncbi Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors
    Sara Gandini
    Department of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Cancer 41:2040-59. 2005
    ..Sensitivity analyses investigated reliability of results and publication bias. Latitude and adjustment for phenotype were two study characteristics that significantly influenced the estimates...
  96. ncbi The epidemiology of UV induced skin cancer
    B K Armstrong
    Cancer Research and Registers Division, New South Wales Cancer Council, PO Box 572, Kings Cross 2011, Australia
    J Photochem Photobiol B 63:8-18. 2001
    ....
  97. pmc Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
    Hensin Tsao
    Wellman Laboratories, Department of Dermatology, Massachusetts General Hospital Melanoma Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Invest Dermatol 122:337-41. 2004
    ..These findings suggest the existence of possible cooperation between BRAF activation and PTEN loss in melanoma development...
  98. ncbi Gender differences in UVB-induced skin carcinogenesis, inflammation, and DNA damage
    Jennifer M Thomas-Ahner
    Department of Pathology, Ohio State University, Columbus, Ohio, USA
    Cancer Res 67:3468-74. 2007
    ..These results show a gender bias in skin carcinogenesis and suggest that the gender difference in tumor development is more influenced by the extent of oxidative DNA damage and antioxidant capacities than by inflammatory response...
  99. ncbi Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma
    Foteini Chatzinasiou
    Department of Dermatology, University of Athens Medical School, Andreas Sygros Hospital, Dragoumi 5, Athens 161 21, Greece
    J Natl Cancer Inst 103:1227-35. 2011
    ....
  100. ncbi Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: model systems for equine sarcoids
    Z Q Yuan
    Institute of Comparative Medicine, University of Glasgow Faculty of Veterinary Medicine, Bearsden Road, Glasgow G61 1QH, UK
    Virology 373:352-61. 2008
    ..These findings confirm that the virus has an active role in the induction of sarcoids and the lines will be invaluable for further studies on the role of BPV-1 in sarcoid pathology...
  101. ncbi Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells
    Y N Vashisht Gopal
    Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:8736-47. 2010
    ....

Research Grants77

  1. Developing a murine model for arsenic-induced skin neoplasm
    Mohammad Athar; Fiscal Year: 2010
    ..highly relevant murine model and could lead to important advances in mechanism-based chemoprevention of these skin neoplasms in arsenic-exposed humans...
  2. CYLD Regulation of Epidermal Growth and Neoplasia
    YUNYAN JENNIFER ZHANG; Fiscal Year: 2009
    ..A previously predicted role for the canonical NF-?B pathway in the etiology of skin neoplasms was recently challenged by findings revealing unaltered NF-KB RelA function in the TPA-induced ..
  3. Rapid Field Device For Measuring Arsenic in Water
    Stephen Bunker; Fiscal Year: 2002
    ..Once the arsenic signal is identified, parameters such as the drift gas, gas pressure, laser energy and density, electrospray voltage and drift tube potential will be optimized to achieve ppt arsenic sensitivity. ..
  4. Reducing Errors in the Diagnosis of Melanoma using an Intelligent Tutoring System
    DANA GRZYBICKI; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  5. CALCIUM & CALCIUM BINDING PROTEINS IN THE EPIDERMIS
    JANET FAIRLEY; Fiscal Year: 1990
    ..Results of these studies and the technology employed will be applied to disease states such as psoriasis and skin neoplasms.
  6. SUSCEPTIBILITY DETERMINANTS FOR PHOTOCARCINOGENESIS
    Paul Strickland; Fiscal Year: 1992
    ..In addition, this knowledge may provide insights into 1) the nature of susceptibility determinants for chemical carcinogenesis, and 2) the relationship between tissue regeneration and cancer...
  7. Development of Inhibitors of B-Raf to Treat Melanoma
    NEAL BIRNBERG; Fiscal Year: 2004
    ....
  8. CUTANEOUS ONCOLOGY
    Madeleine Duvic; Fiscal Year: 2004
    ..Young physicians and students who receive advanced training in the proper detection, prevention, and treatment of skin cancers will be a resource and may improve outcomes for patients of the future. ..
  9. Dendritic Cell Vaccination During Lymphoid Reconstitution
    Jeffrey Weber; Fiscal Year: 2008
    ..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
  10. Development of an electrical diagnostic for melanoma
    Richard Nuccitelli; Fiscal Year: 2008
    ..If the handheld BFI is able to reliably detect malignant skin lesions, it will improve the quality of life for tens of thousands of dermatology patients in the United States alone. [unreadable] [unreadable] [unreadable]..
  11. Role of CRH in skin physiology and pathology
    Andrzej Slominski; Fiscal Year: 2004
    ..g., melanocytes and keratinocytes, and test the role of CRH/CRH-R1 axis in the regulation of human hair growth. ..
  12. MECHANISTIC STUDIES ON TEA AND CARCINOGENESIS
    Chung Yang; Fiscal Year: 2005
    ..The applicant and colleagues will address key issues concerning the bioavailability and bioactivities of O-methyl, glucuronide, and sulfate derivatives and two ring-fission metabolites of tea catechins. ..
  13. INHIBITION OF CARCINOGENESIS BY TEA AND TEA CONSTITUENTS
    Chung Yang; Fiscal Year: 2005
    ..Jointly, we intend to make major contributions to the use of tea for the I chemoprevention of cancer. ..
  14. Reactivation Methylation-Silenced Genes by Polyphenols
    Chung Yang; Fiscal Year: 2007
    ..5. To determine whether EGCG, alone or in combination with other agents, can prevent hypermethylation of genes and tumor development in the intestinal tumorigenesis model in the Min mice. ..
  15. Development of a nanosecond pulsed electric field system to treat skin cancer
    Richard Nuccitelli; Fiscal Year: 2008
    ..It offers a scar-free alternative to surgery that could improve the quality of life for tens of thousands of dermatology patients. [unreadable] [unreadable] [unreadable]..
  16. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  17. VITAMIN D AND THE DIFFERENTIATION OF KERATINOCYTES
    Daniel Bikle; Fiscal Year: 2003
    ..abstract_text> ..
  18. The Secondary Prevention of Melanoma
    Susan Oliveria; Fiscal Year: 2007
    ..abstract_text> ..
  19. ESOPHAGEAL ADENOCARCINOGENESIS AND ITS PREVENTION
    Chung Yang; Fiscal Year: 2007
    ..These studies are expected to fully elucidate the roles of oxidative stress and aberrant AA metabolism in the formation of EAC and help develop effective agents for its prevention. ..
  20. REGULATION OF INTESTINAL CALCIUM TRANSPORT BY VITAMIN D
    Daniel Bikle; Fiscal Year: 2001
    ..These manipulations will all be tested for their ability to block 1,25D-stimulated calcium transport. ..
  21. RAS/BRAF Melanoma Mutations: Precursors, Risk, Prognosis
    Nancy Thomas; Fiscal Year: 2004
    ..This study is also expected to lead to identification of new chemotherapeutic targets and more efficient testing of inhibitors for NRAS and BRAF signaling, which have recently been developed. ..
  22. Diffusing Sun Safe Policies and Environments to Schools
    David Buller; Fiscal Year: 2008
    ..On-site observations of sun protection policies, environmental features, and employee clothing will validate principal reports. [unreadable] [unreadable]..
  23. Development of Survivin as a Vaccine Target for Pancreatic Cancer
    Laszlo Radvanyi; Fiscal Year: 2007
    ..The epitope identification technology used in this project will also be critical in defining other future potential PC antigens. [unreadable] [unreadable] [unreadable]..
  24. DGK in T Cell Regulation and Tolerance
    Thomas F Gajewski; Fiscal Year: 2010
    ..Ti U,0 ._0 ... ur tow 5a' c' OUP O-0 N-0 0-0 V,12 oar aux. :E, -'1 .., (gyp afl' coo COD m='(Dm o03-' _=c 3m03 l17 CDG'O COB 111 ..
  25. Biochemical/Molecular Changes Upon Naive T Cell Priming
    Thomas Gajewski; Fiscal Year: 2005
    ....
  26. Combined Natural Inhibitors in Skin Cancer Prevention
    THOMAS SLAGA; Fiscal Year: 2007
    ..abstract_text> ..
  27. Long-Term Outcomes of Nonmelanoma Skin Cancer
    Mary Margaret Chren; Fiscal Year: 2009
    ..The results will also provide a basis for planning controlled trials of different treatments of NMSC, to guide decisions about the use of resources for this common tumor. ..
  28. Diffusion of an Effective Skin Cancer Prevention Program
    Karen Glanz; Fiscal Year: 2007
    ..The findings will make a significant contribution to our understanding of skin cancer prevention behaviors of individuals and aquatics organizations. ..
  29. PROJECT ALLIFE-EXERCISE AND LEUKEMIA SURVIVORS
    Kevin Oeffinger; Fiscal Year: 2006
    ..This study will represent the first clinical trial aimed at increasing physical activity in leukemia survivors and will advance our understanding of this vulnerable population. ..
  30. Solar Exposure and Melanoma Survival
    Marianne Berwick; Fiscal Year: 2009
    ..2. Determine whether functional polymorphic variants in the vitamin D receptor affect survival from melanoma. 3. Investigate the interaction of lifetime solar exposure and polymorphisms in VDR and its effect on survival. ..
  31. CTLA-4 Inhibition and Autoimmunity in Melanoma
    Jeffrey Weber; Fiscal Year: 2008
    ..abstract_text> ..
  32. Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis
    Pengbo Zhou; Fiscal Year: 2010
    ..abstract_text> ..
  33. GR Impairment in Carconogenesis: Tumor Suppressor Role
    THOMAS SLAGA; Fiscal Year: 2009
    ..4) To analyze the effects of dissociated glucocorticoids on skin inflammation, keratinocyte proliferation, and on skin tumor development. ..
  34. Quantification of the environmental UVA exposure
    Michael Kimlin; Fiscal Year: 2008
    ..abstract_text> ..
  35. Risk Perception/Communications/Reduction Behaviors
    Lois Loescher; Fiscal Year: 2008
    ..Results of this research will be used to formulate a model of risk processes and develop future behavioral interventions to reduce cancer risk. ..
  36. Stress & UV-induced Squamous Cell Carcinoma
    Firdaus S Dhabhar; Fiscal Year: 2010
    ..These studies are important in light of increasing morbidity and mortality associated with skin cancer, the ubiquitous nature of stress, and our preliminary findings on the effects of stress on SCC. ..
  37. Analysis of the Familial Component to Disease in a Biomedical Resource w/Link...
    LISA CANNON ALBRIGHT; Fiscal Year: 2010
    ..component to many health and disease related traits not previously studied, and will eventually lead to the identification and understanding of disease predisposition, risk-modifying, and disease-associated and health-associated genes ..
  38. T Cell Responsiveness and Homeostasis in Anti-Tumor
    Thomas F Gajewski; Fiscal Year: 2010
    ..T cell transduction and tumor transfectants will be examined using factors identified to be useful from the TCR Tg model and mechanisms of improved tumor control will be dissected. ..
  39. Regulation of Nucleotide Excision Repair by Proteolysis
    Pengbo Zhou; Fiscal Year: 2008
    ..abstract_text> ..
  40. Mammography and High-Risk Survivors of Pediatric Cancer
    Kevin Oeffinger; Fiscal Year: 2005
    ....
  41. Technologies To Block Gene Expression in Normal T Cells
    Thomas Gajewski; Fiscal Year: 2003
    ..abstract_text> ..
  42. IL-12 as an Adjuvant for a Melanoma Peptide Vaccine
    Jeffrey Weber; Fiscal Year: 2003
    ..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
  43. HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA
    Jeffrey Weber; Fiscal Year: 2003
    ..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
  44. T CELL RESPONSE TO GENETICALLY ENGINEERED AND MATURED DC
    Bijay Mukherji; Fiscal Year: 2003
    ..These studies will provide a much needed understanding of the rules of engagement of DC and CD4+ T cells with translational implications. ..
  45. IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA
    Jeffrey Weber; Fiscal Year: 2003
    ....
  46. MODULATION BY TEA OF EARLY EFFECTS OF UV ON SKIN
    Allan Conney; Fiscal Year: 2003
    ..abstract_text> ..
  47. MAPPING INTRACRANIAL ANEURYSM SUSCEPTIBILITY LOCI
    Lisa Cannon Albright; Fiscal Year: 2001
    ....
  48. BAYESIAN APPROACHES TO MODEL SELECTION FOR SURVIVAL DATA
    Joseph Ibrahim; Fiscal Year: 2001
    ..We will also develop efficient MCMC computational models for computing model probabilities and Bayes factors. ..
  49. PEPTIDE AND APC BASED MELANOMA VACCINE
    Bijay Mukherji; Fiscal Year: 2001
    ....
  50. ENHANCING THE INTRACELLULAR FUNCTIONING OF HIV RIBOZYMES
    John Rossi; Fiscal Year: 2001
    ..The results from this program will greatly facilitate the effective use of ribozyme treatment for HIV-1 infection in a gene therapy setting. ..
  51. MECHANISMS OF HOTSPOT MUTAGENESIS BY (+)-BPDE
    Allan Conney; Fiscal Year: 2001
    ..We will subsequently examine how the adduct position and chirality affect the outcome of the mutation formation. ..
  52. COMPREHENSIVE OUTCOME OF NONMELANOMA SKIN CANCER
    Mary Margaret Chren; Fiscal Year: 2005
    ..abstract_text> ..
  53. The Risk of Cancer in Fanconi Anemia Heterozygotes
    Marianne Berwick; Fiscal Year: 2005
    ..Analyses will be undertaken to evaluate the role of Fanconi anemia heterozygosity for cancer. If carriers are found to be at increased risk, this information can be used to target individuals for cancer prevention strategies. ..
  54. Multi-Peptide/IL 12 Melanoma Vaccine
    Thomas Gajewski; Fiscal Year: 2006
    ..Understanding these mechanisms will illuminate the next level of intervention to develop to increase the clinical response to the immunotherapy of melanoma. [unreadable] [unreadable]..
  55. Molecular Dissection of T Cell Anergy
    Thomas Gajewski; Fiscal Year: 2005
    ..Ultimately, a complete understanding of the anergic state on the molecular level should guide the development of novel pharmacologic therapies to promote or reverse peripheral tolerance in vivo. ..
  56. PKC Delta as a Tumor Suppressor for Human Skin Cancer
    Mitchell F Denning; Fiscal Year: 2010
    ..These studies will also enhance our understanding of basic apoptotic signaling pathways relevant to many normal and disease processes. ..
  57. Rescuing CTL from Activation Induced Death
    Bijay Mukherji; Fiscal Year: 2010
    ..abstract_text> ..
  58. Overcoming DC defects in cancer patients by VEGF trap
    Jeffrey Sosman; Fiscal Year: 2005
    ..Thereby, the correlative studies described here may lead to the establishment of VEGF inhibition, VEGF Trap, specifically, as an approach to combine with and enhance cancer immunotherapy. ..
  59. Effects of TPA on Leukemia and Solid Tumors
    Allan Conney; Fiscal Year: 2006
    ..Blood levels of TPA that are associated with inhibition of tumor growth will be determined. The effect of inhibitors of tumor growth on proliferation and apoptosis in the tumors will be determined. ..
  60. Protein Knockout Technology/Molecular Analysis of Cancer
    Pengbo Zhou; Fiscal Year: 2004
    ....
  61. Mapping and Cloning Prostate Cancer Predisposition Loci
    Lisa Cannon Albright; Fiscal Year: 2004
    ..This proposal supports the University of Utah high-risk pedigree collection and analysis, and some Myriad genotyping effort towards this goal. ..
  62. Dendritic cell defects in cutaneous T-cell lymphoma
    Alain Rook; Fiscal Year: 2007
    ..abstract_text> ..
  63. Investigation of a Behavioral Substitute for Sunbathing
    Sherry Pagoto; Fiscal Year: 2007
    ..Prevention interventions that target high-risk segments of the community in settings where risk behavior occurs have potential for a large and focused public health impact. [unreadable] [unreadable] [unreadable]..
  64. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2008
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  65. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2009
    ....
  66. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2008
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. [unreadable] [unreadable] [unreadable]..
  67. Prevention of skin cancer by green tea polyphenols
    Santosh Katiyar; Fiscal Year: 2009
    ..Importantly, worldwide interest in green tea as a cancer chemopreventive agent for humans is increasing because it is non-toxic, affordable, popular beverage and is effective in a wide range of organs. ..
  68. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..
  69. Increasing CRC Screening in Health Plan Members
    Karen Glanz; Fiscal Year: 2007
    ..abstract_text> ..
  70. Chemoprevention of Skin Cancer - DFMO Phase III Trial
    Howard Bailey; Fiscal Year: 2005
    ..Ototoxicity and gastrointestinal toxicity have been most common). The objectives, which are unchanged from our original proposal, are all on schedule to be completed in the next 1-2 years. ..
  71. Proanthocyanidins: Novel Skin Cancer Preventive Agent
    Santosh Katiyar; Fiscal Year: 2006
    ..Prevention of skin cancer risk will result to protect and prolong the human health and lives. ..
  72. DFMO Prevention Study (2b) in Organ Transplant Subjects
    Howard Bailey; Fiscal Year: 2005
    ..abstract_text> ..
  73. Telephone E-Health Communication for Improving Glaucoma Treatment Compliance
    Karen Glanz; Fiscal Year: 2009
    ..The findings from this study can inform future public health interventions for improving treatment compliance in vision health and other chronic conditions that require compliance with medication and other treatments. ..
  74. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  75. Prevention of Photocarcinogenesis by antioxidant
    Santosh Katiyar; Fiscal Year: 2003
    ..abstract_text> ..